Balchem Corporation (BCPC) is set to report its Q4 2024 earnings on February 21, 2025. The consensus EPS forecast is $1.11, representing a 35.37% increase year-over-year. The company has shown strong financial performance, with record Q4 sales of $240 million and a net income rise of 26% to $34 million. Management has expressed optimism for 2025, driven by growth in the Human Nutrition & Health segment and recovery in the Animal Nutrition & Health market.
The stock is currently trading at $172.67, with a relative strength index (RSI) of 65.02, indicating a neutral position. The MACD line is above the signal line, suggesting bullish momentum. Fibonacci resistance levels indicate a first resistance at $176.64 and a second at $180.50, with a pivot point at $170.40.
The stock has a forward P/E ratio of 40.84, higher than the industry average of 16.80, reflecting expectations of strong earnings growth. Analysts have set a target price of $198.00, implying a 24.47% upside potential.
Based on strong earnings expectations, positive technical indicators, and analyst sentiment, the stock is expected to rise next week. The target price for the next trading week is $178.50. It is recommended to buy BCPC at current levels, with a stop-loss at $170.40.
The price of BCPC is predicted to go up -15.01%, based on the high correlation periods with AP. The similarity of these two price pattern on the periods is 96.94%.
BCPC
AP